Literature DB >> 17999380

Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Bronwen Martin1, Erin Golden, Alex Keselman, Matthew Stone, Mark P Mattson, Josephine M Egan, Stuart Maudsley.   

Abstract

Huntington's disease (HD) is a tremendously debilitating disorder that strikes relatively young individuals and progresses rapidly over the next ten to fifteen years inducing a loss of cognitive and motor skills and eventually death occurs. The primary locus of the disorder is a polyglutamine expansion of the protein product of the huntingtin (htt) gene. The htt protein appears to be a scaffolding protein that orchestrates the complex assembly of multiple intracellular proteins involved in multiple processes, including vesicular movement and cell metabolism. The htt protein is ubiquitously expressed in human tissues but the predominance of the interest in the pathology lies in its effects on the central nervous system (CNS). Most of the current therapeutics for HD thus have been targeted at preventing neuronal damage in the CNS, however, a considerable body of evidence has been accumulating to suggest that the maintenance of a healthy nervous system is tightly linked with peripheral physiological health. Therefore treatment of both the peripheral and central pathophysiologies of HD could form the basis of a more effective HD therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17999380      PMCID: PMC2657556          DOI: 10.14670/HH-23.237

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  124 in total

1.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

Review 2.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

3.  Tetrabenazine for Huntington's chorea.

Authors:  C A Soutar
Journal:  Br Med J       Date:  1970-10-03

4.  Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.

Authors:  B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 5.  Excitotoxic injury of the neostriatum: a model for Huntington's disease.

Authors:  M DiFiglia
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

6.  Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington's disease.

Authors:  Yasin Temel; Chunyan Cao; Rinske Vlamings; Arjan Blokland; Hatice Ozen; Harry W M Steinbusch; Kimmo A Michelsen; Stephan von Hörsten; Christoph Schmitz; Veerle Visser-Vandewalle
Journal:  Neurosci Lett       Date:  2006-08-14       Impact factor: 3.046

7.  Creatine supplementation lowers brain glutamate levels in Huntington's disease.

Authors:  Andreas Bender; Dorothee P Auer; Thomas Merl; Ralf Reilmann; Phillip Saemann; Alexander Yassouridis; Julia Bender; Adolf Weindl; Matthias Dose; Thomas Gasser; Thomas Klopstock
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

8.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

9.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

10.  Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.

Authors:  Michael Skogen; Jennifer Roth; Sarah Yerkes; Hetal Parekh-Olmedo; Eric Kmiec
Journal:  BMC Neurosci       Date:  2006-10-02       Impact factor: 3.288

View more
  28 in total

1.  To be or not to be--obese.

Authors:  Stuart Maudsley; Bronwen Martin; Josephine M Egan
Journal:  Endocrinology       Date:  2011-10       Impact factor: 4.736

Review 2.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

3.  Role of Mutant TBP in Regulation of Myogenesis on Muscle Satellite Cells.

Authors:  Dong-Ming Zhao; Sui-Qiang Zhu; Fu-Rong Wang; Shan-Shan Huang
Journal:  Curr Med Sci       Date:  2019-10-14

Review 4.  Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.

Authors:  Liyun Wang; Bronwen Martin; Randall Brenneman; Louis M Luttrell; Stuart Maudsley
Journal:  J Pharmacol Exp Ther       Date:  2009-08-10       Impact factor: 4.030

Review 5.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

6.  Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Authors:  Bronwen Martin; Wayne Chadwick; Wei-na Cong; Nick Pantaleo; Caitlin M Daimon; Erin J Golden; Kevin G Becker; William H Wood; Olga D Carlson; Josephine M Egan; Stuart Maudsley
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

7.  Reprogramming Huntington monkey skin cells into pluripotent stem cells.

Authors:  Anthony W S Chan; Pei-Hsun Cheng; Adam Neumann; Jin-Jing Yang
Journal:  Cell Reprogram       Date:  2010-10       Impact factor: 1.987

8.  Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.

Authors:  Kurt R Weiss; Yoko Kimura; Wyan-Ching Mimi Lee; J Troy Littleton
Journal:  Genetics       Date:  2011-11-17       Impact factor: 4.562

Review 9.  Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Exp Gerontol       Date:  2009-07-19       Impact factor: 4.032

10.  Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism.

Authors:  Jane Y Chen; Conny Tran; Lin Hwang; Gang Deng; Michael E Jung; Kym F Faull; Michael S Levine; Carlos Cepeda
Journal:  J Huntingtons Dis       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.